These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 8847067)
1. A comparative immunohistochemical study of malignant mesothelioma and renal cell carcinoma: the diagnostic utility of Leu-M1, Ber EP4, Tamm-Horsfall protein and thrombomodulin. Attanoos RL; Goddard H; Thomas ND; Jasani B; Gibbs AR Histopathology; 1995 Oct; 27(4):361-6. PubMed ID: 8847067 [TBL] [Abstract][Full Text] [Related]
2. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. Attanoos RL; Webb R; Dojcinov SD; Gibbs AR Histopathology; 2002 Mar; 40(3):237-44. PubMed ID: 11895489 [TBL] [Abstract][Full Text] [Related]
3. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study. Ordóñez NG Mod Pathol; 2006 Jan; 19(1):34-48. PubMed ID: 16056246 [TBL] [Abstract][Full Text] [Related]
4. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study. Ordóñez NG Hum Pathol; 2004 Jun; 35(6):697-710. PubMed ID: 15188136 [TBL] [Abstract][Full Text] [Related]
5. A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours. Garcia-Prats MD; Ballestin C; Sotelo T; Lopez-Encuentra A; Mayordomo JI Histopathology; 1998 May; 32(5):462-72. PubMed ID: 9639123 [TBL] [Abstract][Full Text] [Related]
6. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Comin CE; Novelli L; Boddi V; Paglierani M; Dini S Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372 [TBL] [Abstract][Full Text] [Related]
7. The value of 'mesothelium-associated' antibodies in distinguishing between metastatic renal cell carcinomas and mesotheliomas. Osborn M; Pelling N; Walker MM; Fisher C; Nicholson AG Histopathology; 2002 Oct; 41(4):301-7. PubMed ID: 12383211 [TBL] [Abstract][Full Text] [Related]
8. The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies. Ordóñez NG Am J Surg Pathol; 1997 Dec; 21(12):1399-408. PubMed ID: 9414183 [TBL] [Abstract][Full Text] [Related]
9. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature. Ordóñez NG Am J Clin Pathol; 1998 Jan; 109(1):85-9. PubMed ID: 9426522 [TBL] [Abstract][Full Text] [Related]
10. Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions. Delahaye M; van der Ham F; van der Kwast TH Diagn Cytopathol; 1997 Aug; 17(2):115-20. PubMed ID: 9258618 [TBL] [Abstract][Full Text] [Related]
11. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Ordóñez NG Am J Surg Pathol; 2003 Aug; 27(8):1031-51. PubMed ID: 12883236 [TBL] [Abstract][Full Text] [Related]
12. Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms. Attanoos RL; Dojcinov SD; Webb R; Gibbs AR Histopathology; 2000 Sep; 37(3):224-31. PubMed ID: 10971698 [TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis. Carella R; Deleonardi G; D'Errico A; Salerno A; Egarter-Vigl E; Seebacher C; Donazzan G; Grigioni WF Am J Surg Pathol; 2001 Jan; 25(1):43-50. PubMed ID: 11145250 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies. Roberts F; Harper CM; Downie I; Burnett RA Am J Clin Pathol; 2001 Aug; 116(2):253-62. PubMed ID: 11488073 [TBL] [Abstract][Full Text] [Related]
15. Malignant mesothelioma: a comparison of biopsy and postmortem material by light microscopy and immunohistochemistry. Roberts F; McCall AE; Burnett RA J Clin Pathol; 2001 Oct; 54(10):766-70. PubMed ID: 11577123 [TBL] [Abstract][Full Text] [Related]
16. HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura. Kennedy AD; King G; Kerr KM J Clin Pathol; 1997 Oct; 50(10):859-62. PubMed ID: 9462271 [TBL] [Abstract][Full Text] [Related]
17. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma. Ordóñez NG Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877 [TBL] [Abstract][Full Text] [Related]
18. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study. Lucas DR; Pass HI; Madan SK; Adsay NV; Wali A; Tabaczka P; Lonardo F Histopathology; 2003 Mar; 42(3):270-9. PubMed ID: 12605647 [TBL] [Abstract][Full Text] [Related]
19. Claudin-4 shows superior specificity for mesothelioma vs non-small-cell lung carcinoma compared with MOC-31 and Ber-EP4. Naso JR; Churg A Hum Pathol; 2020 Jun; 100():10-14. PubMed ID: 32333920 [TBL] [Abstract][Full Text] [Related]
20. Utility of the antibodies CA 19-9, HBME-1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology. Fetsch PA; Abati A; Hijazi YM Cancer; 1998 Apr; 84(2):101-8. PubMed ID: 9570213 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]